ArticleFrontiers in medicine2025
Global burden and forecast of malignant neoplasms of bone and articular cartilage from 1990 to 2030.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant neoplasms of bone and articular cartilage (MNBAC) are rare but highly lethal cancers, disproportionately affecting children and adolescents. Despite their clinical significance, comprehensive global assessments of their burden and long-term trends remain scarce. Methods: Using Global Burden of Disease (GBD) 2021 data (1990-2021), we estimated age-standardized incidence (ASIR), death (ASDR), and disability-adjusted life years (DALY ASR) across 21 geographic and 5 sociodemographic index (SDI) regions. Temporal trends were quantified with estimated annual percentage change (EAPC). Polynomial regression across 1990-2021 was used to assess the association between SDI and disease burden. Age-sex stratification, age-period-cohort (APC) modeling, and Bayesian APC (BAPC) projections to 2030 were conducted. Results: Globally, the MNBAC burden modestly increased over three decades. High-SDI regions experienced declining trends, whereas middle- and low-middle-SDI regions showed substantial increases in incidence and mortality. The polynomial regression analysis revealed that there was an overall negative correlation between SDI and disease burden, but a significant nonlinear relationship existed. Adolescents and older adults carried the highest incidence, with males more frequently affected. Cohort analyses revealed increasing risks in middle-SDI populations, and projections indicate a continuing rise in burden in these regions by 2030, while stabilization or decline is expected elsewhere. Conclusion: Although rare, MNBAC imposes a growing global health burden, particularly in middle-SDI regions and vulnerable populations. Recognizing the nonlinear link between socioeconomic development and disease burden highlights the need for stage-specific strategies, including strengthening early diagnosis, equitable access to care, and targeted prevention strategies is critical to reducing future disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.